Open AccessTargeting apoptosis in cancer therapy
Author(s) -
Benedito A. Carneiro,
Wafik S. ElDeiry
Publication year - 2020
Publication title -
nature reviews. clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 12.214
H-Index - 155
eISSN - 1759-4782
pISSN - 1759-4774
DOI - 10.1038/s41571-020-0341-y
Subject(s) - apoptosis , programmed cell death , medicine , cancer research , dna damage , cancer , cancer cell , translation (biology) , immune system , bioinformatics , immunology , biology , dna , genetics , messenger rna , gene
For over three decades, a mainstay and goal of clinical oncology has been the development of therapies promoting the effective elimination of cancer cells by apoptosis. This programmed cell death process is mediated by several signalling pathways (referred to as intrinsic and extrinsic) triggered by multiple factors, including cellular stress, DNA damage and immune surveillance. The interaction of apoptosis pathways with other signalling mechanisms can also affect cell death. The clinical translation of effective pro-apoptotic agents involves drug discovery studies (addressing the bioavailability, stability, tumour penetration, toxicity profile in non-malignant tissues, drug interactions and off-target effects) as well as an understanding of tumour biology (including heterogeneity and evolution of resistant clones). While tumour cell death can result in response to therapy, the selection, growth and dissemination of resistant cells can ultimately be fatal. In this Review, we present the main apoptosis pathways and other signalling pathways that interact with them, and discuss actionable molecular targets, therapeutic agents in clinical translation and known mechanisms of resistance to these agents.